Publications by authors named "J C Horiot"
Importance: Prognostic factors of ipsilateral breast tumor recurrence (IBTR) may change over time following breast-conserving therapy.
Objective: The EORTC "boost no boost" trial showed that young age and high-grade invasive carcinoma were the most important risk factors for IBTR. This study reanalyses pathological prognostic factors related to IBTR using long-term follow-up.
Regional treatment is driven by surgery and radiotherapy in early breast cancer patients as sole or combined modalities. Lymph node dissection, performed in patients with positive sentinel lymph nodes accurately identifies malignant spread in the nodal areas and ensures high levels of control in the axilla. At the turn of the century, its real impact on survival indices was nevertheless questioned, also in terms of therapeutic index, by cooperative groups and meta-analyses.
View Article and Find Full Text PDFWhole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
Lancet Oncol
January 2015
Article Synopsis
- A phase 3 randomized controlled trial assessed the effects of a 16 Gy radiation boost on survival and recurrence in patients with stage I and II breast cancer following breast-conserving treatment, with 20-year follow-up results reported.
- The study included 5,318 patients, comparing outcomes between those who received the boost versus those who did not, showing a slight difference in overall survival rates (59.7% vs. 61.1%) with no significant statistical difference.
- Patients receiving the radiation boost had a lower incidence of ipsilateral breast tumor recurrence (12.0%) compared to those without the boost (16.4%), suggesting that the boost may help reduce local recurrences despite similar overall survival rates.
Consider a single intraoperative fraction for patients eligible for hypofractionated regimens?
Oncology (Williston Park)
June 2014
Intraoperative radiotherapy of breast carcinomas consists of a single irradiation session delivered to the surgical bed, immediately after the tumor resection. This modality, denoted in the literature as IORT, represents a novel therapeutic approach, the application of which is rigorously codified according to the risk factors identified at the time of diagnosis. As definitive treatment, IORT is applied to patients in post-menopausal status, presenting a small tumor with favorable pathological features.
View Article and Find Full Text PDF